Matica Biotechnology is a cell and gene therapy CDMO devoted to the production of viral vectors and cell-based products used in cell and gene therapies and other genetic medicines. Founded in 2019 by its parent company, CHA Biotech, Matica Bio’s services include GMP production in suspension platform cell and virus banking. The company’s adeno-associated virus and lentivirus production capabilities aim to help streamline the development and manufacturing cycles to best support its clients in the production of cell and gene therapy vaccines and applications.
Visit Company Website
